質子幫浦阻斷劑的市場規模、佔有率和成長分析（按藥物類型、給藥途徑、劑型、處方藥、適應症和地區）：產業預測（2024-2031）

2022 年質子幫浦阻斷劑的全球市場規模約為 46.5 億美元，高於 2023 年的 49 億美元，預測期內（2024-2031 年）和 2031 年的複合年成長率為 5.2%。億。

質子幫浦阻斷劑（PPI）是製藥業的重要組成部分，主要用於治療胃腸道疾病，如消化性潰瘍、柔林格症候群和胃食道逆流（GERD）。這些藥物透過抑制胃內壁的質子幫浦來發揮作用，有效降低胃酸水平。全球酸相關疾病的激增正在推動對非處方 (OTC) PPI 的需求，這種趨勢以及藥物配方的不斷進步正在推動人口老化，而這往往需要此類治療。然而，市場面臨一些挑戰，例如由於專利到期、監管障礙以及對長期使用質子幫浦抑制劑相關的長期副作用的擔憂而導致學名藥的競爭加劇。儘管存在這些障礙，市場仍然充滿機遇，特別是配方創新、數位健康技術的整合以及消費者對自我治療的偏好不斷增加。這些動態表明，PPI 在應對日益成長的健康挑戰、同時適應不斷變化的消費者偏好和醫療保健服務系統方面具有巨大潛力。總體而言，雖然市場正在克服某些挑戰，但對有效胃腸道治療的持續需求支撐了市場的彈性和對未來成長的預期。

目錄

介紹

• 分析目的
• 定義
• 市場範圍

分析方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 創新矩陣
• 主要投資機會
• 市場生態系統
• 價值鏈分析
• 技術分析
• 監管分析
• 臨床試驗分析
• 客戶和購買標準分析

質子幫浦阻斷劑市場：依藥物類型

• 市場概況
• Esomeprazole
• 奧美拉唑
• 地克蘭索拉唑
• 泮托拉唑
• Rabeprazole
• 蘭索拉唑
• 其他

質子幫浦阻斷劑市場：依給藥途徑

• 市場概況
• 口服
• 注射

質子幫浦阻斷劑市場：按劑型

• 市場概況
• 錠劑
• 膠囊
• 注射藥物
• 其他

質子幫浦阻斷劑市場：依處方藥分類

• 市場概況
• 品牌
• 非專利的

質子幫浦阻斷劑市場：依跡象分類

• 市場概況
• 胃食道逆流症
• 胃灼熱
• 消化性潰瘍
• 其他

質子幫浦阻斷劑市場：按分銷管道

• 市場概況
• 醫院藥房
• 零售藥房
• 藥局/診所
• 其他

質子幫浦阻斷劑市場：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• 阿斯特捷利康（英國）
• 輝瑞公司（美國）
• 武田製藥公司（日本）
• 拜耳公司（德國）
• 葛蘭素史克公司（英國）
• 雷迪博士實驗室有限公司（印度）
• 梯瓦製藥工業股份有限公司（以色列）
• 太陽製藥工業有限公司（印度）
• 賽諾菲公司（法國）
• Pharma Dynamics (Pty) Ltd.（南非）
• 艾伯維公司（美國）
• 羽扇豆有限公司（印度）
• 衛材株式會社（日本）
• 卡迪拉醫療保健有限公司 (Zydus Cadila)（印度）
• 西普拉有限公司（印度）
• 默克公司（美國）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Torrent 製藥有限公司（印度）
• RedHill Biopharma Ltd.（以色列）
• 住友大日本製藥有限公司（日本）

Global Proton Pump Inhibitors Market size was valued at around USD 4.65 billion in 2022 and is expected to rise from USD 4.90 billion in 2023 to reach a value of USD 7.35 billion by 2031, at a CAGR of 5.2% over the forecast period (2024-2031).

Proton pump inhibitors (PPIs) represent a significant segment within the pharmaceutical industry, primarily addressing gastrointestinal disorders like peptic ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD). These medications function by inhibiting proton pumps in the stomach lining, effectively reducing stomach acid levels. The global surge in acid-related conditions is propelling the demand for over-the-counter (OTC) PPIs, a trend further intensified by an aging population that often requires such treatments, alongside continuous advancements in drug formulations. However, the market faces challenges from the expiration of patents, which has led to heightened competition from generic alternatives, as well as regulatory hurdles and concerns regarding the long-term side effects associated with prolonged PPI usage. Despite these obstacles, opportunities abound in the market, particularly through innovations in drug formulations, the integration of digital health technologies, and a growing consumer inclination towards self-medication. These dynamics indicate a robust potential for PPIs in addressing rising health challenges while adapting to the evolving landscape of consumer preferences and healthcare delivery systems. Overall, while the market navigates certain challenges, the continual demand for effective gastrointestinal treatments underscores its resilience and promise for future growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proton Pump Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proton Pump Inhibitors Market Segmental Analysis

Global Proton Pump Inhibitors Market is segmented by Drug Type, Route of Administration, Dosage Form, Prescription, Indication, Distribution Channel and region. Based on Drug Type, the market is segmented into Esomeprazole, Omeprazole, Dexlansoprazole, Pantoprazole, Rabeprazole, Lansoprazole, and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Dosage Form, the market is segmented into Tablet, Capsules, Injection, and Others. Based on Prescription, the market is segmented into Branded, and Generics. Based on Indication, the market is segmented into Gastroesophageal Reflux Disease, Heartburn, Peptic ulcers, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is being significantly driven by the emergence of innovative formulations and delivery systems that enhance the therapeutic efficacy and safety profiles of these medications. The introduction of extended-release PPIs allows for improved patient compliance and more effective management of acid-related disorders. Furthermore, the development of combination therapies, where PPIs are synergistically used with other therapeutic agents, caters to the treatment of complex gastrointestinal conditions, thereby expanding their clinical applicability. This modernization in drug development not only meets evolving patient needs but also fosters a competitive landscape, propelling the overall market growth of PPIs.

Restraints in the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market faces significant restraints due to the adverse health effects associated with prolonged use of these medications. Risks such as increased chances of bone fractures, kidney disease, and deficiencies in crucial vitamins like magnesium and B12 are prompting healthcare professionals to exercise greater caution in prescribing PPIs. This heightened vigilance may lead to reduced prescription rates, ultimately suppressing market growth. Additionally, the potential for long-term PPI use to contribute to Clostridium difficile infections poses further challenges, complicating treatment protocols and negatively impacting patient outcomes, thereby affecting the overall demand for these products in the healthcare industry.

Market Trends of the Global Proton Pump Inhibitors Market

The Global Proton Pump Inhibitors (PPIs) market is experiencing a notable trend towards the introduction of alternatives and innovative formulations designed to improve treatment outcomes while minimizing side effects. Researchers are actively developing novel delivery systems, including combination therapies and delayed-release formulations to enhance efficacy. Concurrently, there's a burgeoning interest in alternative therapies such as prokinetic agents and H2-receptor antagonists, alongside dietary modifications to manage acid-related disorders more effectively. This shift not only reflects the growing demand for personalized medicine but also addresses concerns regarding long-term PPI use, ultimately reshaping the landscape of acid suppression treatments.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Innovation Matrix
• Top Investment Pockets
• Ecosystem of the Market
• Value Chain Analysis
• Technology Analysis
• Regulatory Analysis
• Clinical trials Analysis
• Customer & Buying Criteria Analysis

Proton Pump Inhibitors Market, By Drug Type

• Market Overview
• Esomeprazole
• Omeprazole
• Dexlansoprazole
• Pantoprazole
• Rabeprazole
• Lansoprazole
• Others

Proton Pump Inhibitors Market, By Route of Administration

• Market Overview
• Oral
• Injectable

Proton Pump Inhibitors Market, By Dosage Form

• Market Overview
• Tablet
• Capsules
• Injection
• Others

Proton Pump Inhibitors Market, By Prescription

• Market Overview
• Branded
• Generics

Proton Pump Inhibitors Market, By Indication

• Market Overview
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic ulcers
• Others

Proton Pump Inhibitors Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores and Clinics
• Others

Proton Pump Inhibitors Market, by region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharma Dynamics (Pty) Ltd. (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare Ltd. (Zydus Cadila) (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RedHill Biopharma Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments